Guide
Tirzepatide Alternatives 2026: Nine Options, Ranked by What You Are Solving
The right alternative depends on why you are switching. For cost, an approved oral at $149 or compounded at $186. For cardiovascular evidence, semaglutide and its SELECT
The right alternative depends on why you are switching. For cost, an approved oral at $149 or compounded at $186. For cardiovascular evidence, semaglutide and its SELECT trial. For a pill, Foundayo or oral Wegovy. For coverage, whichever molecule your plan actually lists.
What does the comparison actually show?
| If you are solving for | Option | Monthly | Evidence |
|---|---|---|---|
| Lowest cost, approved | Foundayo or oral Wegovy | $149 | 12.4% / 15.1% |
| Lowest cost, compounded | Compounded semaglutide | $145 | No trial of its own |
| Lowest cost, same molecule | Compounded tirzepatide | $186 | No trial of its own |
| Cardiovascular evidence | Semaglutide (Wegovy) | $349 | SELECT: 20% MACE reduction |
| Maximum weight loss | Tirzepatide (Zepbound) | $299–$449 | 22.5% |
| Diabetes coverage | Mounjaro or Ozempic | ~$25 with card | Easier to get covered |
| No injections | Foundayo | $149 | No food or water restriction |
| Medicare | Bridge programme | $50 | Prior authorisation required |
| Not an alternative | Berberine and supplements | — | ~4–5 lb; not FDA-approved |
Check coverage before any of this. A covered brand with a savings card commonly lands near $25, which beats every cash route on this page by a wide margin, and one phone call settles whether it applies to you.
The last row is on the table deliberately. Supplements marketed as GLP-1 substitutes are not alternatives in any measurable sense — roughly 4 to 5 pounds against 22.5% of body weight — and leaving them off the comparison would let the claim stand unanswered.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
What does each route cost?
| Route | Monthly | Twelve months | Evidence |
|---|---|---|---|
| Commercial cover plus savings card | $25 | $300 | Provider-reported |
| Medicare GLP-1 Bridge | $50 | $600 | Reported |
| Compounded, 12-month, flat | $186 | $2,232 | Captured at source |
| Compounded, month-to-month, flat | $215 | $2,580 | Captured at source |
| Brand Zepbound, LillyDirect vials | $299–$449 | $4,788 | Captured at source |
| Brand Zepbound, retail pens | ~$1,060 | ~$12,720 | Third-party claim |
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $215 | $195 | $190 | $186 | $2,232 |
| Microdose | $189 | $159 | $150 | $147 | $1,764 |
| Sublingual ODT | $229 | $219 | $205 | $199 | $2,388 |
Flat at every covered dose within each protocol, read on the provider’s own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
| Trial | Population | Result | Duration |
|---|---|---|---|
| SURMOUNT-1 | Obesity or overweight, no diabetes | 22.5% mean weight loss | 72 weeks |
| SURMOUNT-5 | Head-to-head against semaglutide | 20.2% vs 13.7% | 72 weeks |
| SURPASS-2 | Type 2 diabetes | Superior HbA1c reduction | 40 weeks |
| SURMOUNT-OSA | Obstructive sleep apnoea with obesity | Large AHI reduction | 52 weeks |
Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
What is the best alternative to tirzepatide?
It depends what you are solving for: an approved oral at $149 for cost, semaglutide for cardiovascular evidence, a pill for no injections, or whichever molecule your plan covers.
Is there a cheaper drug that works as well?
No approved option matches tirzepatide's 22.5% in SURMOUNT-1. The approved orals report 12.4% and 15.1% at $149.
Are supplements a real alternative?
No. Berberine meta-analyses report roughly 4 to 5 pounds against 22.5% of body weight for tirzepatide, and it is not FDA-approved for weight loss.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Ro Body vs Hims & HersComparisons
- Cheapest FDA-Approved vs Compounded GLP-1 OptionsJournal
- Brand-Name vs Compounded TirzepatidePillar / Money
- Brand-Name vs Compounded GLP-1Comparisons
- Zepbound vs MounjaroComparisons
- Zepbound vs Compounded TirzepatidePillar / Money
- Zepbound vs Compounded TirzepatideComparisons
Related coverage
- Tirzepatide 3-Month Plans: What the Middle Term Actually Saves
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- GLP-1s and Bone: What Rapid Weight Loss Does to a Skeleton
- GLP-1s and the Gallbladder: Rapid Weight Loss Is the Risk Factor
- GLP-1s and Gastroparesis: Where Intended Effect Ends and Diagnosis Begins
- GLP-1s and the Kidneys: Demonstrated Benefit and a Dehydration Route to Harm
- GLP-1s and Mental Health: What the Regulatory Reviews Concluded
- GLP-1s and Pregnancy: Not Recommended, and the Planning That Follows
GLP-1 Tirzepatide Rank. “Tirzepatide Alternatives 2026: Nine Options, Ranked by What You Are Solving.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-alternatives-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.